Aidoc IPO
Aidoc provides AI-powered radiology solutions that help radiologists prioritize urgent cases and detect critical findings in medical imaging. The company's FDA-cleared algorithms assist with identifying conditions like pulmonary embolism and brain bleeds. Investors are interested in its comprehensive radiology AI platform and growing adoption in healthcare systems.
Key Facts
| Industry | Medical AI |
| Founded | 2016 |
| Headquarters | Tel Aviv, Israel |
| Employees | ~200 |
| Website | aidoc.com |
| Funding | Series D (or latest round) at $150M raised, led by Goldman Sachs. Total raised: $290M+ |
About Aidoc
Aidoc develops AI-powered solutions for radiology departments, specializing in computer vision technology that helps radiologists detect and prioritize critical findings in medical imaging. The company's AI algorithms are designed to identify conditions like pulmonary embolism, brain bleeds, and other time-sensitive pathologies in CT scans, enabling faster diagnosis and treatment decisions.
The platform integrates directly into hospital workflows and PACS systems, providing real-time analysis of medical images without disrupting existing radiologist workflows. Aidoc has achieved FDA clearance for multiple AI solutions and is deployed across hundreds of medical centers globally, positioning itself as a leader in the rapidly growing medical AI market focused on improving patient outcomes through faster, more accurate diagnoses.
IPO Status
Aidoc recently raised $150 million in a funding round led by Goldman Sachs, with multiple credible sources reporting that the company is eyeing an IPO. The April 2026 funding round was explicitly positioned as a pre-IPO raise, signaling the company's intention to go public in the near future. While no specific IPO timeline or S-1 filing has been announced, the combination of substantial institutional backing from Goldman Sachs and public statements about IPO plans indicate serious preparations for a public offering. As a prominent player in the radiology AI market focused on reducing diagnostic errors in hospitals, Aidoc has attracted significant investor interest in the growing healthcare technology sector. The company's focus on product development and market expansion continues, now with the added strategic objective of preparing for public markets. The substantial funding and Goldman Sachs involvement suggest strong institutional confidence in the company's IPO prospects.
Competitors
Frequently Asked Questions
Does Aidoc have a stock?
No, Aidoc has not had an IPO and remains a privately held company. The company has not announced any plans to go public.
When is the Aidoc IPO date?
There is no announced IPO date for Aidoc, as the company has not revealed plans to go public. No confirmed timeline has been reported.
How can I buy Aidoc stock?
Aidoc stock is not publicly available for purchase since the company is private. Shares may only be accessible to accredited investors through private funding rounds.
Stay Updated on the Aidoc IPO
Get real-time alerts when Aidoc files for an IPO, prices shares, or begins trading.
Get IPO Alerts